The role of α-agonists in glaucoma therapy

Research output: Contribution to journalReview articlepeer-review

Abstract

α-Agonists are a relatively old class of medications, the topical use of which lowers eye pressure. Clonidine was introduced for this use in 1966, brimonidine in 1974, and apraclonidine in 1978. Initial short-term attempts to use clonidine were complicated by problems with systemic hypotension. Apraclonidine is more polar and less lipophilic than clonidine. This probably allows less penetration into both the posterior segment of the eye and systemic circulation, allowing for an excellent therapeutic index. The prophylactic use of apraclonidine (1% and 0.5%) has dramatically changed the safety profile for many anterior segment laser procedures, cataract surgery, and vitrectomy. The role of α-agonists in the chronic treatment of glaucoma is still uncertain. Potential benefits of additional lowering of intraocular pressure must be weighed against the following potential disadvantages: tachyphalaxsis, posterior segment vasoconstriction, psychologic depression and fatigue, syncope and systemic hypotension, and a topical allergy-like syndrome.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalCurrent opinion in ophthalmology
Volume8
Issue number2
DOIs
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'The role of α-agonists in glaucoma therapy'. Together they form a unique fingerprint.

Cite this